Search Results - "Koch, K.M"

Magnetic resonance imaging near metal implants by Koch, K.M., Hargreaves, B.A., Pauly, K. Butts, Chen, W., Gold, G.E., King, K.F.

“…The desire to apply magnetic resonance imaging (MRI) techniques in the vicinity of embedded metallic hardware is increasing. The soft‐tissue contrast available…”
Get full text

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer by Bonnefoi, H, Zaman, K, Debled, M, Fiche, M, Fournier, M, Nobahar, M, Pierga, J-Y, Koch, K.M, Bartlett, J, Zimmer, A, Marreaud, S, Bogaerts, J, Cameron, D

“…Abstract Background Lapatinib is an effective anti-HER2 therapy in advanced breast cancer and docetaxel is one of the most active agents in breast cancer…”
Get full text

5084 Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen by Cardoso, F, Koch, K.M, Brain, E, Lokiec, F, Marreaud, S, Bogaerts, J, Fumoleau, P

Get full text

5073 Lapatax: Safety profile of neoadjuvant lapatinib combined with docetaxel in Her 2/neu overexpressing breast cancer – EORTC protocol 10054 by Bonnefoi, H, Zaman, K, Nobaher, M, Brain, E, Pierga, J.Y, Koch, K.M, Bartlett, J, Marreaud, S, Bogaerts, J, Cameron, D

Get full text

Quantitative Susceptibility Mapping after Sports-Related Concussion by Koch, K M, Meier, T B, Karr, R, Nencka, A S, Muftuler, L T, McCrea, M

“…Quantitative susceptibility mapping using MR imaging can assess changes in brain tissue structure and composition. This report presents preliminary results…”
Get full text

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer by Crown, J., Kennedy, M.J., Tresca, P., Marty, M., Espie, M., Burris, H.A., DeSilvio, M., Lau, M.R., Kothari, D., Koch, K.M., Diéras, V.

“…This phase IB, open-label, dose-escalation study evaluated the safety, tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with…”
Get full text

LTB4 in nephrotoxic serum nephritis in rats by Fauler, J., Wiemeyer, A., Marx, K.H., Kühn, K., Koch, K.M., Frölich, J.C.

“…LTB4 in nephrotoxic serum nephritis in rats. We studied leukotriene B4 (LTB4) synthesis in isolated glomeruli of rats with nephrotoxic serum nephritis. This…”
Get full text

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan by Midgley, R.S., Kerr, D.J., Flaherty, K.T., Stevenson, J.P., Pratap, S.E., Koch, K.M., Smith, D.A., Versola, M., Fleming, R.A., Ward, C., O'Dwyer, P.J., Middleton, M.R.

“…This study determined the optimally tolerated regimen (OTR) of oral lapatinib administered in combination with infusional 5-fluorouracil (5-FU), leucovorin and…”
Get full text

My best wishes for the future of Clinical Nephrology by Koch, K M

Get more information

Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy by Baldamus, C A, Ernst, W, Frei, U, Koch, K M

“…Sympathetic and hemodynamic response to a constant volume removal was investigated during pure ultrafiltration, hemofiltration, acetate hemodialysis, and…”
Get more information

Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient by Floege, J, Brandis, A, Nonnast-Daniel, B, Westhoff-Bleck, M, Tiedow, G, Linke, R P, Koch, K M

“…beta 2-Microglobulin (beta 2M)-derived amyloidosis has become a major concern in long-term hemodialysis patients. Clinical symptomatology is largely restricted…”
Get more information

Influence of antihypertensive therapy on renal function by Frei, U, Schindler, R, Koch, K M

“…Antihypertensive therapy influences kidney function by different mechanisms depending on the mode of action of the drug used. The GFR is improved by calcium…”
Get full text

270 POSTER Recombinant human IL-18 (iboctadekin) PKPD and clinical activity in phase I-II by Koch, K.M., Jaworski, D., Kirby, L., Kathman, S., Bell, B., Robertson, M., Mier, J., Logan, T., Kirwood, J., Dar, M.M.

Get full text

Orientation toward natural and artificial grassbeds by swimming bay scallops, Argopecten irradians (Lamarck, 1819) by Hamilton, P.V., Koch, K.M.

“…The orientation of swimming in bay scallops was studied in the field using natural and artificial grassbeds as potential directional cues. Scallops released on…”
Get full text

267 Pharmacokinetics and pharmacodynamics of recombinant human IL-18 (rhIL-18) in patients with solid tumors by Koch, K.M., Kwok, D., McIntosh, T., Godillot, P., Rykaczewski, L., Conway, T.M., Leonard, E., Srour, E., Panka, D., Dar, M.M.

Get full text

Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients by Kliem, V, Boeck, A, Eisenberger, U, Petersen, R, Radermacher, J, Hiss, M, Pethig, M, Koch, K.M, Nashan, B, Brunkhorst, R

Get full text

Relationship between HLA status and hepatitis B virus (HBV) infection in caucasians by Kliem, V., Chen, D.-F., Endres, W., Brunkhorst, R., Tillmann, H.L., Koch, K.M., Manns, M.P., Stangel, W.

Get full text

HLA status and hepatitis C virus (HCV) infection in caucasians with end-stage renal disease (ESRD) by Endres, W., Chen, D.-F., Kliem, V., Tillmann, H.L., Brunkhorst, R., Koch, K.M., Manns, M.P., Stangel, W.

Get full text

Tacrolimus for Steroid- and OKT3-Resistant Rejection in Kidney Recipients by Kliem, V, Petersen, R, Ehlerding, G, Schaumann, D, Eisenberger, U, Koch, K.M, Pichlmayr, R, Brunkhorst, R

Get full text

Successful Therapy of Chronic Renal Allograft Failure by Enhanced Immunosuppression by Kliem, V, Tiroke, T, Ehlerding, G, Eberhard, O, Behrend, M, Frei, U, Koch, K.M, Pichlmayr, R, Brunkhorst, R

Get full text